BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+5.04%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.97B
AUM Growth
-$106M
(-1.5%)
Cap. Flow
-$278M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$25.6M |
| 2 |
Celldex Therapeutics
CLDX
|
$24.6M |
| 3 |
Exact Sciences
EXAS
|
$12.1M |
| 4 |
Tandem Diabetes Care
TNDM
|
$12M |
| 5 |
Charles River Laboratories
CRL
|
$6.28M |
Top Sells
| 1 |
RDUS
Radius Health, Inc.
RDUS
|
$91.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
$42.4M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$26.3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$20.3M |
| 5 |
Axsome Therapeutics
AXSM
|
$14.3M |
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0.59% |
| 3 | Energy | 0.02% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Kosmos Energy
KOS
$784M
| $1.65M | 0.02% |
318,300
| – | – |
|
127
Cencora
COR
$56.7B
| $1.61M | 0.02% |
11,910
-1,090
| -8% | -$148K |
|
128
Neuropace
NPCE
$322M
| $1.46M | 0.02% |
388,368
-119,562
| -24% | -$448K |
|
129
Akero Therapeutics
AKRO
$3.58B
| $1.42M | 0.02% |
+41,634
| New | +$1.42M |
|
130
Zai Lab
ZLAB
$3.42B
| $1.28M | 0.02% |
+36,600
| New | +$1.28M |
|
131
Krystal Biotech
KRYS
$4.35B
| $1.28M | 0.02% |
18,300
+4,900
| +37% | +$342K |
|
132
Repligen
RGEN
$7.01B
| $1.24M | 0.02% |
+6,600
| New | +$1.24M |
|
|
CELL
133
DELISTED
PhenomeX Inc. Common Stock
CELL
| $1.1M | 0.02% |
385,014
| – | – |
|
134
Seer Inc
SEER
$118M
| $1.05M | 0.02% |
136,133
| – | – |
|
135
Agilent Technologies
A
$36.5B
| $1.05M | 0.02% |
+8,627
| New | +$1.05M |
|
136
McKesson
MCK
$85.5B
| $999K | 0.01% |
2,938
+401
| +16% | +$136K |
|
137
Denali Therapeutics
DNLI
$2.26B
| $951K | 0.01% |
+31,000
| New | +$951K |
|
138
Viridian Therapeutics
VRDN
$1.53B
| $946K | 0.01% |
46,100
-2,900
| -6% | -$59.5K |
|
|
ONC
139
BeOne Medicines Ltd. American Depositary Shares
ONC
$37.6B
| $940K | 0.01% |
+7,000
| New | +$940K |
|
140
Labcorp
LH
$23.2B
| $799K | 0.01% |
4,540
-407
| -8% | -$71.6K |
|
|
INBX
141
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $781K | 0.01% |
43,500
-33,100
| -43% | -$594K |
|
142
Caribou Biosciences
CRBU
$174M
| $699K | 0.01% |
66,300
-4,000
| -6% | -$42.2K |
|
143
Dr. Reddy's Laboratories
RDY
$11.9B
| $664K | 0.01% |
62,000
| – | – |
|
144
Xencor
XNCR
$610M
| $660K | 0.01% |
25,400
-1,100
| -4% | -$28.6K |
|
145
SPDR S&P 500 ETF Trust
SPY
$660B
| $643K | 0.01% |
+1,800
| New | +$643K |
|
146
Design Therapeutics
DSGN
$367M
| $583K | 0.01% |
+34,881
| New | +$583K |
|
147
Alphabet (Google) Class C
GOOG
$2.84T
| $577K | 0.01% |
6,000
| – | – |
|
148
Merus
MRUS
$5.1B
| $509K | 0.01% |
+25,400
| New | +$509K |
|
149
Bristol-Myers Squibb
BMY
$96B
| $502K | 0.01% |
7,062
-17,845
| -72% | -$1.27M |
|
150
SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$1.85B
| $486K | 0.01% |
+3,900
| New | +$486K |
|